The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of efficacy of bevacizumab plus chemotherapy in management of malignant pleural effusion (MPE) in non-squamous non-small cell lung cancer (NSCLC) patients with MPE unsuccessfully controlled by tube drainage or pleurodesis (North East Japan Study Group Trial NEJ-013B-2).
 
Rintaro Noro
No Relationships to Disclose
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma
 
Jiro Usuki
No Relationships to Disclose
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masaru Nishitsuji
No Relationships to Disclose
 
Hiroaki Okamoto
Research Funding - Astellas Oncology; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; MSD Oncology; Taiho Pharmaceutical
 
Mitsunori Hino
No Relationships to Disclose
 
Koichi Hagiwara
Honoraria - AstraZeneca Japan
Patents, Royalties, Other Intellectual Property - LSI Medience Corporation
 
Akihiko Miyanaga
No Relationships to Disclose
 
Masahiro Seike
No Relationships to Disclose
 
Kaoru Kubota
Honoraria - AstraZeneca Japan; BMS Brazil; Boehringer Ingelheim; Chugai Pharma; MSD Oncology; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim; Daiichi Sankyo; Ono Pharmaceutical; Taiho Pharmaceutical
 
Akihiko Gemma
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma